;PMID: 12049480
;source_file_618.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..49] = [t:0..49]
;1)section:[e:55..197] = [t:55..197]
;2)section:[e:201..250] = [t:201..249]
;3)section:[e:254..324] = [t:254..323]
;4)sentence:[e:328..700] = [t:328..700]
;5)sentence:[e:701..979] = [t:701..979]
;6)sentence:[e:980..1207] = [t:980..1207]
;7)sentence:[e:1208..1319] = [t:1208..1319]
;8)section:[e:1320..1474] = [t:1320..1474]
;9)section:[e:1478..1523] = [t:1478..1522]
;Sentence Matching Errors
;ERROR_Section end mismatch[e:201..250][t:201..249]
;ERROR_Section end mismatch[e:254..324][t:254..323]
;ERROR_Section end mismatch[e:1478..1523][t:1478..1522]
;Token/POS Errors
;ERROR_Token in entity file but not tree[40..41] )
;ERROR_Token in entity file but not tree[41..42] :
;ERROR_Token in entity file but not tree[249..250] .
;ERROR_Token in entity file but not tree[323..324] .
;ERROR_Token in entity file but not tree[1522..1523] ]
;ERROR_Token in tree file but not entity[40..42] ):

;section 0 Span:0..49
;Anticancer Drug Des. 2001 Aug-Oct;16(4-5):217-25.
(SEC
  (FRAG (NNP:[0..10] Anticancer) (NNP:[11..15] Drug) (NNP:[16..19] Des)
        (.:[19..20] .) (CD:[21..25] 2001) (NNP:[26..30] Aug-) (CD:[30..33] Oct)
        (::[33..34] ;) (CD:[34..36] 16) (-LRB-:[36..37] -LRB-) (CD:[37..38] 4)
        (HYPH:[38..39] -) (CD:[39..40] 5) (-RRB-:[40..42] -RRB-:)
        (CD:[42..45] 217) (HYPH:[45..46] -) (CD:[46..48] 25) (.:[48..49] .)))

;section 1 Span:55..197
;1-[(Benzofuran-2-yl)phenylmethyl]triazoles as steroidogenic inhibitors: 
;synthesis and in vitro inhibition of human placental CYP19 aromatase.
;[55..97]:substance:"1-[(Benzofuran-2-yl)phenylmethyl]triazoles"
;[101..125]:substance:"steroidogenic inhibitors"
;[181..196]:cyp450:"CYP19 aromatase"
(SEC
  (NP-HLN
    (NP
      (NP
          (NNS:[55..97] 1--LSB--LRB-Benzofuran-2-yl-RRB-phenylmethyl-RSB-triazoles))
      (PP (IN:[98..100] as)
        (NP (JJ:[101..114] steroidogenic) (NNS:[115..125] inhibitors))))
    (::[125..126] :)
    (NP
      (NP
        (NP (NN:[128..137] synthesis))
        (CC:[138..141] and)
        (NP
          (ADJP (FW:[142..144] in) (FW:[145..150] vitro))
          (NN:[151..161] inhibition)))
      (PP (IN:[162..164] of)
        (NP (JJ:[165..170] human) (JJ:[171..180] placental)
           (NN:[181..186] CYP19) (NN:[187..196] aromatase))))
    (.:[196..197] .)))
;ERROR_Entity in section[55..97]:substance
;"1-[(Benzofuran-2-yl)phenylmethyl]triazoles"
;ERROR_Entity in section[101..125]:substance "steroidogenic inhibitors"
;ERROR_Entity in section[181..196]:cyp450 "CYP19 aromatase"

;section 2 Span:201..249
;Vinh TK, Yee SW, Kirby AJ, Nicholls PJ, Simons C
(SEC
  (FRAG (NNP:[201..205] Vinh) (NNP:[206..208] TK) (,:[208..209] ,)
        (NNP:[210..213] Yee) (NNP:[214..216] SW) (,:[216..217] ,)
        (NNP:[218..223] Kirby) (NNP:[224..226] AJ) (,:[226..227] ,)
        (NNP:[228..236] Nicholls) (NNP:[237..239] PJ) (,:[239..240] ,)
        (NNP:[241..247] Simons) (NNP:[248..249] C)))

(ORPH .)

;section 3 Span:254..323
;Medicinal Chemistry, Welsh School of Pharmacy, Cardiff University, UK
(SEC
  (FRAG (NNP:[254..263] Medicinal) (NNP:[264..273] Chemistry) (,:[273..274] ,)
        (NNP:[275..280] Welsh) (NNP:[281..287] School) (IN:[288..290] of)
        (NNP:[291..299] Pharmacy) (,:[299..300] ,) (NNP:[301..308] Cardiff)
        (NNP:[309..319] University) (,:[319..320] ,) (NNP:[321..323] UK)))
;ERROR_Orphan Text from Tree File[249..254] .

(ORPH .)

;sentence 4 Span:328..700
;Hormone-dependent breast cancer is stimulated by the female hormones oestrone
; and oestradiol, therefore compounds which inhibit the specific enzymes
;involved  in the formation of the nitogenic hormones, namely CYP19 aromatase
;(P450arom)  and 17beta-hydroxysteroid dehydrogenase (17beta-HSD) type 1, are
;targets of  therapeutic interest for the treatment of breast cancer.
;[328..335]:substance:"Hormone"
;[388..396]:substance:"hormones"
;[397..405]:substance:"oestrone"
;[411..421]:substance:"oestradiol"
;[433..442]:substance:"compounds"
;[470..477]:cyp450:"enzymes"
;[512..530]:substance:"nitogenic hormones"
;[539..554]:cyp450:"CYP19 aromatase"
;[556..564]:cyp450:"P450arom"
;[571..626]:substance:"17beta-hydroxysteroid dehydrogenase (17beta-HSD) type
;1"
;[632..639]:substance:"targets"
(SENT
  (S
    (S
      (NP-SBJ-2
        (ADJP (NN:[328..335] Hormone) (HYPH:[335..336] -)
              (JJ:[336..345] dependent))
        (NN:[346..352] breast) (NN:[353..359] cancer))
      (VP (VBZ:[360..362] is)
        (VP (VBN:[363..373] stimulated)
          (NP-2 (-NONE-:[373..373] *))
          (PP (IN:[374..376] by)
            (NP-LGS
              (NP (DT:[377..380] the) (JJ:[381..387] female)
                  (NNS:[388..396] hormones))
              (NP (NN:[397..405] oestrone) (CC:[407..410] and)
                  (NN:[411..421] oestradiol)))))))
    (,:[421..422] ,)
    (S
      (ADVP (RB:[423..432] therefore))
      (NP-SBJ
        (NP (NNS:[433..442] compounds))
        (SBAR
          (WHNP-1 (WDT:[443..448] which))
          (S
            (NP-SBJ-1 (-NONE-:[448..448] *T*))
            (VP (VBP:[449..456] inhibit)
              (NP
                (NP (DT:[457..460] the) (JJ:[461..469] specific)
                    (NNS:[470..477] enzymes))
                (VP (VBN:[478..486] involved)
                  (NP (-NONE-:[486..486] *))
                  (PP-CLR (IN:[488..490] in)
                    (NP
                      (NP (DT:[491..494] the) (NN:[495..504] formation))
                      (PP (IN:[505..507] of)
                        (NP
                          (NP (DT:[508..511] the)
                             (JJ:[512..521] nitogenic) (NNS:[522..530] hormones))
                          (,:[530..531] ,)
                          (NP
                            (ADVP (RB:[532..538] namely))
                            (NP
                              (NP (NN:[539..544] CYP19)
                                  (NN:[545..554] aromatase))
                              (NP (-LRB-:[555..556] -LRB-)
                                  (NN:[556..564] P450arom)
                                  (-RRB-:[564..565] -RRB-)))
                            (CC:[567..570] and)
                            (NP
                              (NML
                                (NML (NN:[571..592] 17beta-hydroxysteroid)
                                     (NN:[593..606] dehydrogenase))
                                (NML (-LRB-:[607..608] -LRB-)
                                     (NN:[608..618] 17beta-HSD)
                                     (-RRB-:[618..619] -RRB-)))
                              (NN:[620..624] type) (CD:[625..626] 1)))))))))))))
      (,:[626..627] ,)
      (VP (VBP:[628..631] are)
        (NP-PRD
          (NP (NNS:[632..639] targets))
          (PP (IN:[640..642] of)
            (NP (JJ:[644..655] therapeutic) (NN:[656..664] interest)))
          (PP (IN:[665..668] for)
            (NP
              (NP (DT:[669..672] the) (NN:[673..682] treatment))
              (PP (IN:[683..685] of)
                (NP (NN:[686..692] breast) (NN:[693..699] cancer))))))))
    (.:[699..700] .)))
;ERROR_Orphan Text from Tree File[323..328] .

;sentence 5 Span:701..979
;A series of novel  1-[(benzofuran-2-yl)phenylmethyl]1,2,4-triazoles were
;prepared using a  three-step synthesis and evaluated for their inhibitory
;activity against human  placental aromatase in vitro, using
;[1,2,6,7-3H]androstenedione as the substrate  for the aromatase enzyme.
;[720..768]:substance:"1-[(benzofuran-2-yl)phenylmethyl]1,2,4-triazoles"
;[882..891]:cyp450:"aromatase"
;[908..935]:substance:"[1,2,6,7-3H]androstenedione"
;[943..952]:substance:"substrate"
;[962..978]:cyp450:"aromatase enzyme"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[701..702] A) (NN:[703..709] series))
      (PP (IN:[710..712] of)
        (NP (JJ:[713..718] novel)
            (NNS:[720..768] 1--LSB--LRB-benzofuran-2-yl-RRB-phenylmethyl-RSB-1,2,4-triazoles))))
    (VP
      (VP (VBD:[769..773] were)
        (VP (VBN:[774..782] prepared)
          (NP-1 (-NONE-:[782..782] *))
          (S-MNR
            (NP-SBJ (-NONE-:[782..782] *))
            (VP (VBG:[783..788] using)
              (NP (DT:[789..790] a)
                (NML (CD:[792..797] three) (HYPH:[797..798] -)
                     (NN:[798..802] step))
                (NN:[803..812] synthesis))))))
      (CC:[813..816] and)
      (VP (VBN:[817..826] evaluated)
        (NP-1 (-NONE-:[826..826] *))
        (PP (IN:[827..830] for)
          (NP
            (NP (PRP:[831..836] their) (JJ:[837..847] inhibitory)
                (NN:[848..856] activity))
            (PP (IN:[857..864] against)
              (NP (JJ:[865..870] human) (JJ:[872..881] placental)
                  (NN:[882..891] aromatase)))))
        (ADVP (FW:[892..894] in) (FW:[895..900] vitro))
        (,:[900..901] ,)
        (S-MNR
          (NP-SBJ (-NONE-:[901..901] *))
          (VP (VBG:[902..907] using)
            (NP (NN:[908..935] -LSB-1,2,6,7-3H-RSB-androstenedione))
            (PP (IN:[936..938] as)
              (NP
                (NP (DT:[939..942] the) (NN:[943..952] substrate))
                (PP (IN:[954..957] for)
                  (NP (DT:[958..961] the)
                     (NN:[962..971] aromatase) (NN:[972..978] enzyme)))))))))
    (.:[978..979] .)))

;sentence 6 Span:980..1207
;Inhibitory activity was dependent on both substituent  and position of
;substitution, with introduction of small electron-withdrawing  groups in the
;phenyl ring showing optimum activity (IC50 ranging from 0.065 to  2.02
;microm).
;[1166..1170]:quantitative-name:"IC50"
;[1184..1198]:quantitative-value:"0.065 to  2.02"
;[1199..1205]:quantitative-units:"microm"
(SENT
  (S
    (NP-SBJ (JJ:[980..990] Inhibitory) (NN:[991..999] activity))
    (VP (VBD:[1000..1003] was)
      (ADJP-PRD (JJ:[1004..1013] dependent)
        (PP (IN:[1014..1016] on)
          (NP (DT:[1017..1021] both)
            (NP (NN:[1022..1033] substituent))
            (CC:[1035..1038] and)
            (NP (NN:[1039..1047] position)
              (PP (IN:[1048..1050] of)
                (NP (NN:[1051..1063] substitution)))))))
      (,:[1063..1064] ,)
      (PP (IN:[1065..1069] with)
        (NP
          (NP (NN:[1070..1082] introduction))
          (PP (IN:[1083..1085] of)
            (NP
              (NP (JJ:[1086..1091] small)
                (NML (NN:[1092..1100] electron) (HYPH:[1100..1101] -)
                     (VBG:[1101..1112] withdrawing))
                (NNS:[1114..1120] groups))
              (VP-2 (-NONE-:[1120..1120] *ICH*))))
          (PP-LOC (IN:[1121..1123] in)
            (NP (DT:[1124..1127] the) (NN:[1128..1134] phenyl)
                (NN:[1135..1139] ring)))
          (VP-2 (VBG:[1140..1147] showing)
            (NP (JJ:[1148..1155] optimum) (NN:[1156..1164] activity))
            (PRN (-LRB-:[1165..1166] -LRB-)
              (S
                (NP-SBJ (NN:[1166..1170] IC50))
                (VP (VBG:[1171..1178] ranging)
                  (PP (IN:[1179..1183] from)
                    (NP (CD:[1184..1189] 0.065)
                      (NML-3 (-NONE-:[1189..1189] *RNR*))))
                  (PP (TO:[1190..1192] to)
                    (NP (CD:[1194..1198] 2.02)
                      (NML-3 (-NONE-:[1198..1198] *RNR*))))
                  (NML-3 (NN:[1199..1205] microm))))
              (-RRB-:[1205..1206] -RRB-))))))
    (.:[1206..1207] .)))

;sentence 7 Span:1208..1319
;Substitution in the benzofuran ring resulted in a loss of activity  when
;substituted at C-5 (IC50 > 20 microm).
;[1301..1305]:quantitative-name:"IC50"
;[1306..1310]:quantitative-value:"> 20"
;[1311..1317]:quantitative-units:"microm"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1208..1220] Substitution))
      (PP-LOC (IN:[1221..1223] in)
        (NP (DT:[1224..1227] the) (NN:[1228..1238] benzofuran)
            (NN:[1239..1243] ring))))
    (VP (VBD:[1244..1252] resulted)
      (PP-CLR (IN:[1253..1255] in)
        (NP
          (NP (DT:[1256..1257] a) (NN:[1258..1262] loss))
          (PP (IN:[1263..1265] of)
            (NP (NN:[1266..1274] activity)))))
      (SBAR-ADV
        (WHADVP-1 (IN:[1276..1280] when))
        (S
          (NP-SBJ-2 (-NONE-:[1280..1280] *))
          (VP (VBN:[1281..1292] substituted)
            (NP-2 (-NONE-:[1292..1292] *))
            (PP-LOC (NN:[1293..1295] at)
              (NP (NN:[1296..1299] C-5)))
            (ADVP-TMP-1 (-NONE-:[1299..1299] *T*)))))
      (PRN (-LRB-:[1300..1301] -LRB-)
        (S
          (NP-SBJ (NN:[1301..1305] IC50))
          (VP (SYM:[1306..1307] >)
            (NP (CD:[1308..1310] 20) (NN:[1311..1317] microm))))
        (-RRB-:[1317..1318] -RRB-)))
    (.:[1318..1319] .)))

;section 8 Span:1320..1474
;The compounds were all shown to  exhibit weak inhibitory activity against rat
;testes P450 17 (17,20-lyase),  indicating good selectivity towards P450arom.
;[1324..1333]:substance:"compounds"
;[1405..1412]:cyp450:"P450 17"
;[1414..1425]:cyp450:"17,20-lyase"
;[1465..1473]:cyp450:"P450arom"
(SEC
  (S
    (NP-SBJ-1 (DT:[1320..1323] The) (NNS:[1324..1333] compounds))
    (VP (VBD:[1334..1338] were) (DT:[1339..1342] all)
      (VP (VBN:[1343..1348] shown)
        (S
          (NP-SBJ-1 (-NONE-:[1348..1348] *))
          (VP (DT:[1349..1351] to)
            (VP (VB:[1353..1360] exhibit)
              (NP (JJ:[1361..1365] weak) (JJ:[1366..1376] inhibitory)
                  (NN:[1377..1385] activity))
              (PP (IN:[1386..1393] against)
                (NP
                  (NP
                    (NML (DT:[1394..1397] rat) (NNS:[1398..1404] testes))
                     (NN:[1405..1409] P450) (CD:[1410..1412] 17))
                  (NP (-LRB-:[1413..1414] -LRB-) (NN:[1414..1425] 17,20-lyase)
                      (-RRB-:[1425..1426] -RRB-))))
              (,:[1426..1427] ,)
              (S-ADV
                (NP-SBJ (-NONE-:[1427..1427] *))
                (VP (VBG:[1429..1439] indicating)
                  (NP (JJ:[1440..1444] good) (NN:[1445..1456] selectivity))
                  (PP (IN:[1457..1464] towards)
                    (NP (NN:[1465..1473] P450arom))))))))))
    (.:[1473..1474] .)))
;ERROR_Entity in section[1324..1333]:substance "compounds"
;ERROR_Entity in section[1405..1412]:cyp450 "P450 17"
;ERROR_Entity in section[1414..1425]:cyp450 "17,20-lyase"
;ERROR_Entity in section[1465..1473]:cyp450 "P450arom"

;section 9 Span:1478..1522
;PMID: 12049480 [PubMed - indexed for MEDLINE
(SEC
  (FRAG (NNP:[1478..1482] PMID) (::[1482..1483] :) (CD:[1484..1492] 12049480)
        (-LRB-:[1493..1494] -LSB-) (NNP:[1494..1500] PubMed) (::[1501..1502] -)
        (VBN:[1503..1510] indexed) (IN:[1511..1514] for)
        (NNP:[1515..1522] MEDLINE)))
;ERROR_Orphan Text from EOF Tree File[1522..EOF] ]

(ORPH -RSB-)
